Full-Time
Develops, manufactures, markets prescription drugs
$160k - $200k/yr
Columbus, OH, USA
Remote
Remote within the United States; overnight travel 40-60% may be required.
Bachelor's, Master's, MBA
See people who can refer or advise you
ANI Pharmaceuticals develops, manufactures, and markets prescription medications, including generic and branded products, that are FDA-approved. Its medicines are produced in regulated facilities and go through standard safety and efficacy testing to meet patient needs. The company sells these products to pharmacies, hospitals, and healthcare providers, using a portfolio that spans generic drugs and specialty branded therapies. What sets ANI apart is its combination of a diversified product lineup with growth through strategic acquisitions to expand its offerings and market reach, rather than relying on a single product area. Its goal is to provide high-quality medicines to patients while continuously expanding its portfolio and market presence through acquisitions and manufacturing capabilities.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Baudette, Minnesota
Founded
1996
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
Unlimited Paid Time Off
Paid Vacation
Paid Holidays
Employee Stock Purchase Plan
ANI Pharmaceuticals reported second-quarter revenue of $266 million, beating analyst estimates of $259.8 million with 25.9% year-on-year growth. The company's adjusted EPS of $2.21 also surpassed expectations of $2.04. Despite strong performance in rare disease and generics businesses, the market reacted negatively to the results. CEO Nikhil Lalwani highlighted momentum in the third quarter, noting July marked the highest month for new cases initiated. The company reconfirmed its full-year revenue guidance of $1.11 billion at the midpoint and maintained its adjusted EPS guidance of $9.44. Operating margin improved to 15.2%, up from 6.6% in the same quarter last year. Analysts questioned the disconnect between prescription data and revenue, insurance reverification issues, and the rationale behind lowering Cortrophin guidance despite positive demand metrics.
ANI Pharmaceuticals reported Q2 revenues of $266 million, up 25.9% year on year, exceeding analyst expectations by 2.4%. The company beat EPS estimates but slightly missed full-year revenue guidance expectations. Despite posting the fastest revenue growth among the four generic pharmaceuticals stocks tracked, ANI's shares fell 9.1% following the results. The company's portfolio includes 116 pharmaceutical products with a focus on rare disease treatments. Generic pharmaceuticals companies as a group delivered strong Q2 results, with revenues beating consensus estimates by 2.6%. However, the sector has struggled recently, with share prices down 5.6% on average since the latest earnings announcements. The industry faces pricing pressures and thin margins but benefits from consistent demand for affordable medications.
ANI Pharmaceuticals reported Q2 revenue of $266 million, up 25.9% year on year and beating analyst estimates of $259.8 million. The specialty pharmaceutical company's non-GAAP profit of $2.21 per share exceeded consensus by 8.2%. However, the company's full-year revenue guidance of $1.11 billion came in 1% below analyst expectations, prompting a negative market reaction. Management highlighted strong growth in rare disease and generics businesses, driven by expansion of its sales force for Cortrophin Gel. CEO Nikhil Lalwani noted July represented the highest month for new cases initiated. The company is expanding Cortrophin Gel into new specialty areas, particularly gout treatment. Operating margin improved to 15.2% from 6.6% in the prior year period.
ANI Pharmaceuticals reported record second-quarter results, with revenue rising 26% year-over-year to $266 million and adjusted EBITDA increasing 32% to $71.6 million. Adjusted earnings per share reached $2.21. Cortrophin Gel, the company's rare-disease treatment, drove growth with revenue climbing 43% to $117.1 million. ANI expanded its rare-disease sales force by 50% to approximately 180 representatives, including a new gout-focused team. The company maintained its full-year revenue guidance of $1.08 billion to $1.14 billion and adjusted EBITDA guidance of $285 million to $300 million. However, it lowered 2026 Cortrophin guidance to $520 million to $540 million based on first-half results. Cash reached $360.2 million, supported by $115 million in first-half operating cash flow.
ANI Pharmaceuticals reported Q2 2026 revenue of $266 million, beating analyst estimates of $259.8 million and marking 25.9% year-on-year growth. The specialty pharmaceutical company's adjusted earnings per share of $2.21 also exceeded expectations by 8.2%. Despite the strong quarterly performance, ANI's stock dropped following the release. The company's full-year revenue guidance of $1.11 billion came in 1% below analyst estimates. ANI has demonstrated robust long-term growth, with revenue expanding at a 35.6% compound annual growth rate over the past five years. The company's portfolio includes 116 pharmaceutical products and a growing rare disease platform. President and CEO Nikhil Lalwani highlighted the quarter's "outstanding financial results" alongside the implementation of the company's largest rare disease sales force expansion.